PepGen Inc. Common Stock (PEPG) Stock
NASDAQ · PEPG
2.53
Fundamentals
Market cap
$179.38M
Price / Earnings ratio
-2.6x
Price / Sales ratio
N/A
Price / Book ratio
1.6x
Return on assets
-50.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

Business Wire
PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
NeutralPEPGAugust 6, 2026
Business WireNeutral
PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
PEPG

Business Wire
PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review
NeutralPEPGAugust 6, 2026
Business WireNeutral
PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review
PEPG

Business Wire
PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program
NeutralPEPGMay 21, 2026
Business WireNeutral
PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program
PEPG

Zacks Investment Research
PepGen (PEPG) Loses 14.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
NeutralPEPGMay 20, 2026
Zacks Investment ResearchNeutral
PepGen (PEPG) Loses 14.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
PEPG
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy1
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
0000
Debt & Balance Sheet
Total assets
Total liabilities
2025
209M138M69M0
Revenue to Profit
2025$0.0
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-89.7M
Net incomeEarnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

Business Wire
PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
NeutralPEPGAugust 6, 2026
Business WireNeutral
PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
PEPG

Business Wire
PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review
NeutralPEPGAugust 6, 2026
Business WireNeutral
PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review
PEPG

Business Wire
PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program
NeutralPEPGMay 21, 2026
Business WireNeutral
PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program
PEPG

Zacks Investment Research
PepGen (PEPG) Loses 14.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
NeutralPEPGMay 20, 2026
Zacks Investment ResearchNeutral
PepGen (PEPG) Loses 14.3% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
PEPG

Zacks Investment Research
PepGen (PEPG) Upgraded to Buy: Here's What You Should Know
NeutralPEPGMay 13, 2026
Zacks Investment ResearchNeutral
PepGen (PEPG) Upgraded to Buy: Here's What You Should Know
PEPG

Business Wire
PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
NeutralPEPGMay 12, 2026
Business WireNeutral
PepGen Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
PEPG

Business Wire
PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data
NeutralPEPGMarch 30, 2026
Business WireNeutral
PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data
PEPG

Reuters
US FDA puts partial clinical hold on PepGen's muscle disease drug trial
NeutralPEPGMarch 4, 2026
ReutersNeutral
US FDA puts partial clinical hold on PepGen's muscle disease drug trial
PEPG

Business Wire
PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights
NeutralPEPGMarch 4, 2026
Business WireNeutral
PepGen Reports Fourth Quarter and Year-End 2025 Financial Results and Recent Corporate Highlights
PEPG

Business Wire
PepGen Announces Regulatory Updates on FREEDOM2
NeutralPEPGMarch 4, 2026
Business WireNeutral
PepGen Announces Regulatory Updates on FREEDOM2
PEPG
About PepGen Inc. Common Stock
No description available.
SectorHealthcare
IndustryBiotechnology
Employees57
CEODr. James G. McArthur Ph.D.
IPO DateMay 6, 2022
HeadquartersBoston, MA
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. James G. McArthur Ph.D. | President, CEO, Treasurer, Secretary & Director | 1962 |
| Mr. Noel P. Donnelly M.B.A. | Chief Financial Officer | 1970 |
| Mr. Joseph D. Vittiglio Esq., J.D. | Chief Business & Legal Officer and Secretary | 1972 |
| Dr. Kasra Kasraian Ph.D. | Chief Technical Officer | 1967 |
| Ms. Emiko Bryant | Senior Vice President of HR & Administration | — |
| Dr. Hayley Parker Ph.D. | Senior Vice President of Global Regulatory Affairs & Quality | — |
| Dr. Paul D. Streck M.B.A., M.D. | Executive VP and Head of Research & Development | 1964 |
| Ms. Pallavi Lonkar Ph.D. | Vice President & Head of Preclinical | — |
| Ms. Melissa Michaels | Executive Director & Head of Regulatory Affairs CMC | — |
| Mr. Michael Zhao | Vice President & Head of Biometrics | — |
Fundamentals
Valuation
Market cap$179.38M
Price-to-sales ratioN/A
Price-to-book value1.55
Price-earnings ratio-2.60
Return on Equity-60.00%
Return on SalesN/A
Return on Assets-50.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-1.02
Income Statement
Average volume682,385
EBITDA$-75.82M
1 year high (52w)$7.80
1 year low (52w)$1.31
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
1 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$20.00
Est return
690.51%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022 | -13.2 | -9.1 | +9.7 | -10.7 | -6.9 | +31.9 | +15.5 | -4.5 | ||||
| 2023 | +17.2 | -2.7 | -19.8 | +20.0 | +5.0 | -39.4 | -34.1 | +6.1 | -21.4 | +10.3 | -3.9 | +26.6 |
| 2024 | +41.5 | +36.8 | -11.6 | -15.2 | +17.5 | -4.8 | -36.2 | -4.4 | -6.5 | -25.5 | -22.1 | -36.5 |
| 2025 | -65.8 | +152.0 | -49.8 | +19.8 | -0.7 | -22.9 | +25.7 | -12.1 | +285.0 | -1.1 | +42.2 | +12.4 |
| 2026 | -28.5 | +22.4 | -72.9 | -5.7 | -14.3 | +22.4 | -2.8 | +59.0 | -17.0 |



